Articles tagged "Immunosuppression"

2015 American Transplant Congress
Improved Renal Function Post-Liver Transplant With Earlier Everolimus Conversion
S. Lin,¹ M. Zimmerman,² V. Lewis,¹ S. Biggins,³ C. Ruller,⁴ I. Kam,⁴ T. Nydam.⁴
¹Pharmacy Dept, University of Colorado Hospital, Aurora; ²Division of Transplant Surgery, Medical College of Wisconsin, Wisconsin; ³Division of Gastroenterology/Hepatology, University of Colorado, Aurora; ⁴Division of Transplant Surgery, University of Colorado, Aurora.
Calcineurin inhibitors (CNI) play an important role in preventing acute rejection (AR) post-liver transplant. Its long-term use is limited by development of nephrotoxicity. Optimal timing…
2015 American Transplant Congress
The Effect of Compatibility of ABO Blood Type Antigens on Graft Survival of Intestinal Transplants
J. Cai,¹ A. Qing,² G. Wu,³ M. Everly,¹ P. Terasaki.¹
¹Terasaki Foundation Lab, Los Angeles; ²Lincoln High School, Stockton; ³The 4th Military Medical University, Xi-An, China.
Due to the introduction of new immunosuppressive agents and development of pre- and post-transplant patient management, ABO blood group incompatibility is no longer considered an…
2015 American Transplant Congress
Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation
Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ K. Ito,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Applied Immunity, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression was evaluated in clinical outcomes as well as protocol biopsies findings and donor…
2015 American Transplant Congress
Costimulation Blockade Prevents Rejection of Vascularized Composite Allografts
B. Oh,¹ G. Furtmüller,¹ M. Fryer,¹ J. Grahammer,² S. Schneeberger,² D. Cooney,¹ W. Lee,¹ G. Brandacher.¹
¹Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; ²Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria.
[Background] Vascularized composite allotransplantation (VCA) is an emerging new era in transplant medicine and has become a valid therapeutic option after devastating tissue loss. The…
2015 American Transplant Congress
Immunosuppression and Reoperation After Simultaneous Kidney Pancreas Transplantation Convey Greatest Risk for Rejection
C. Bratton, V. Rohan, S. Nadig, J. Mcgillicuddy, K. Chavin, P. Baliga, D. Taber.
MUSC, Charleston, SC.
Background: Episodes of acute cellular rejection (ACR) convey significant morbidity after simultaneous kidney and pancreas transplantation (SPK). The role of recipient sensitization, immunosuppression (IS) and…
2015 American Transplant Congress
Characterization of Peripheral Blood T and B Cells of Sensitized Kidney Transplant Recipients With Long Term Stable Graft Function
N. Galante,¹ M. Fernandes,¹ F. Agena,¹ A. Triboni,¹ G. Freitas,¹ A. Aguirre,¹ W. Nahas,¹ V. Coelho,² E. David-Neto.¹
¹Renal Transplant Service, Hospital das Clínicas - University of Sao Paulo School of Medicine, Sao Paulo, Brazil; ²Laboratory of Immunology, Heart Institute - University of Sao Paulo School of Medicine, Sao Paulo, Brazil.
We examined the phenotype of T and B cells of peripheral blood of sensitized kidney transplant recipients with stable graft function (GFR > 29mL/min) enrolled…
2015 American Transplant Congress
Once Daily Dosing Is as Effective as Twice Daily Dosing of Immediate Release Tacrolimus
L. Bowman,¹ T. Horwedel,¹ J. Hagopian,¹ B. Bone,² H. Wijeweera,² D. Brennan.²
¹Barnes-Jewish Hospital, St. Louis; ²Washington University School of Medicine, St. Louis.
Purpose: Extended release (ER) tacrolimus (tac) has been available as Advagraf® for many years and as Astagraf XL® in the US since 2013. Immediate release…
2015 American Transplant Congress
Post Hoc Subgroup Analysis of ZEUS: Outcome on Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion from a Calcineurin Inhibitor to an Everolimus Based Regimen: 5 Year Follow-Up Data
F. Lehner,¹ K. Budde,¹ R. Wuethrich,² P. Reinke,¹ W. Arns,¹ A. Muehlfeld,¹ U. Eisenberger,¹ R. Stahl,¹ K. Heller,¹ O. Witzke,¹ B. Suwelack,¹ H. Wolters,¹ I. Hauser,¹ M. Porstner,³ C. Sommerer.¹
¹ZEUS Study Group, Germany; ²ZEUS Study Group, Switzerland; ³Novartis, Pharma, Germany.
Background: To study renal function and patient outcome after 5 years in living donation subgroup of kidney de novo transplant recipients after conversion to an…
2015 American Transplant Congress
Generation, Cryopreservation, Function and In Vivo Fate of Ex-Vivo Expanded Cynomolgus
H. Guo,¹ H. Zhang,¹ L. Lu,¹ M. Ezzelarab,¹ A. Thomson.^1,2
¹Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA; ²Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA.
Background:Foxp3+ regulatory T cells (Treg) function to promote immune tolerance and prevent immunopathogenesis. Preclinical studies have demonstrated that adoptive transfer of Treg prevents rejection of…
2015 American Transplant Congress
An Economic Analysis of Tolerance Induction for Two-Haplotype Match Kidney Living Donor Transplant Recipients
K. Erickson,¹ W. Winkelmayer,² R. Lowsky,¹ J. Scandling,¹ S. Strober.¹
¹Medicine, Stanford University, Palo Alto, CA; ²Medicine, Baylor College of Medicine, Houston, TX.
Purpose:Tolerance induction is a novel therapy that enables some living donor kidney transplant recipients (LDKTR) to safely discontinue immunosuppressive (IS) therapy. We examine whether tolerance…